CASE REPORT

Diabetic ketoacidosis and sinus arrest conditions in a patient with an inserted cardiac pacemaker

Takatoshi Anno\(^1\) \* · Kotone Tsujimoto\(^1\) · Ryo Shigemoto\(^1\) · Sunao Kojima\(^2\) · Hideaki Kaneto\(^3\)

Received: 27 August 2020 / Accepted: 4 October 2020 / Published online: 3 January 2021
© The Author(s) 2021

Keywords Sinus arrest · Cardiac pacemaker · Diabetic ketoacidosis

Introduction

It is well known in clinical practice that metabolic acidosis sometimes leads to life-threatening conditions. Acidosis itself is induced by various conditions and diseases, and is classified as either respiratory or metabolic acidosis.

Diabetic ketoacidosis (DKA), a form of metabolic acidosis, is one of the most serious acute metabolic complications of diabetes mellitus (DM), and is often observed in subjects with type 1 DM (T1DM). DKA is characterized by hyperglycemia, metabolic acidosis, and increased total ketone concentrations [1]. Here, we report a case with pre-existing T1DM and an inserted cardiac pacemaker. The patient with partial loss of consciousness was diagnosed with DKA, and she experienced sick sinus syndrome leading to sinus arrest in the presence of regular pulsation maintained by the cardiac pacemaker.

Case Report

A 73-year-old woman with a 33-year history of T1DM visited the emergency room with symptoms of deteriorated consciousness. At 62 years of age a cardiac pacemaker was implanted for the treatment of sick sinus syndrome and paroxysmal atrial fibrillation. Following a diagnosis of dementia, glycemic control using insulin was poor and she was hospitalized three times due to DKA over the course of a single year. Upon admission, her vital signs were: temperature, 38.0 °C; blood pressure, 125/70 mmHg; heart rate, 138 bpm; oxygen saturation, 98%. Inflammation markers were markedly elevated (Table 1): white blood cell, 18900 / μL (neutrophil, 90.0%); C-reactive protein, 2.18 mg/dL; procalcitonin, 6.87 ng/mL. Liver function was close to normal, but renal function was elevated: creatinine, 2.02 mg/dL; blood urea nitrogen, 43 mg/dL. Above all, diabetes-associated data were markedly elevated; plasma glucose, 1044 mg/dL; hemoglobin A1c, 12.8%; glycoalbumin 55.6%. Ketone body concentrations were also markedly elevated: total ketone body, 26020.0 μmol/L; acetoacetate, 7000.0 μmol/L; β-hydroxybuterate, 19020.0 μmol/L. Blood gas analysis showed severe acidosis: pH 7.058; base excess (BE), − 24.7 mEq/L; HCO\(_3\) −, 4.9 mEq/L (Fig. 1).

After admission, we administered 0.9% NaCl and gradually tapered total volume. We also maintained serum potassium levels with drip infusion and continuous, gradually tapered insulin infusion. Potassium levels were 4.5 mmol/L, within the mild-to-moderately elevated range of serum potassium seen under DKA conditions, and infusion of potassium was started after one point of observation to maintain serum potassium levels (Fig. 1). After approximately 5 hours, the patient’s blood pressure suddenly and markedly decreased to 58/26 mmHg. At that time, plasma glucose was decreased to 546 mg/dL and the blood gas analysis data improved (pH, 7.338). Mineral balance including potassium levels were within a normal range after therapy. Immediately prior to the decrease in blood pressure her heart rate was just 50 bpm without fluctuation, as determined by her cardiac pacemaker in DDD mode (see Fig. 1, ① and ②). Examination with echocardiography and abdominal

\(^{1}\) Department of General Internal Medicine 1, Kawasaki Medical School, 2-6-1 Nakasange, Kita-ku, Okayama 700-8505, Japan
\(^{2}\) Department of General Internal Medicine 3, Kawasaki Medical School, Okayama 700-8505, Japan
\(^{3}\) Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki 701-0192, Japan
enhanced computed tomography failed to detect any abnormalities such as ischemic heart disease, pulmonary thromboembolism and aortic dissection. We started vasopressors to rescue her from shock and used sodium bicarbonate, which is not used under DKA conditions except for severe DKA [1], because of the likelihood that the reduction of blood pressure and combined sinus arrest would be caused by DKA. To maintain her blood pressure within the minimum range, it was necessary to change the pacemaker configuration to 80 bpm (Fig. 1, ③). Upon vital sign stabilization, the pacemaker was temporarily configured to 40 bpm to confirm her spontaneous heartbeat (Fig. 1, ④). However, this test failed at that time. About 24 hours after the initial decrease in blood pressure, a spontaneous heartbeat was transiently detected (Fig. 1, ⑤). Finally, about 40 hours after the initial drop in blood pressure, the patient’s spontaneous heartbeat could be steadily detected (Fig. 1 ⑥). Over the 40 duration of this episode blood glucose levels, pH, base excess and HCO$_3^-$ gradually improved. Ketone body levels normalized 2 days later. With treatment and improvement of DKA conditions, the pacemaker-determined waveform was subsequently never observed.

**Table 1** Laboratory data observed in the emergence room

| Variable                        | Result   | Reference range | Variable                        | Result   | Reference range |
|---------------------------------|----------|-----------------|---------------------------------|----------|-----------------|
| Peripheral blood                |          |                 | Dyslipidemia marker             |          |                 |
| White blood cells (μL)          | 18900    | 3300—8600      | Total cholesterol (mg/dL)       | 139      | 142—248         |
| Red blood cells (× 10^3μL)      | 370      | 435—555        | LDL cholesterol (mg/dL)         | 66       | 65—139          |
| Hemoglobin (g/dL)               | 12.1     | 13.7—16.8      | HDL cholesterol (mg/dL)         | 66       | 40—90           |
| Platelets (× 10^3μL)            | 22.4     | 15.8—34.8      | Triglyceride (mg/dL)            | 239      | 40—149          |
| Blood biochemistry              |          |                 |                                 |          |                 |
| Total protein (g/dL)            | 7.1      | 6.6—8.1        | Plasma glucose (mg/dL)          | 1044     | –               |
| Albumin (g/dL)                  | 3.9      | 4.1—5.1        | Hemoglobin A1c (%)              | 12.8     | 4.9—6.0         |
| Globulin (g/dL)                 | 3.2      | 2.2—3.4        | Glycoalbumin (%)                | 55.6     | 12.4—16.3       |
| Total bilirubin (mg/dL)         | 0.4      | 0.4—1.5        | Total ketone body (μmol/L)      | 26020.0  | 0.0—130.0       |
| AST (U/L)                       | 31       | 13—30          | Acetoacetate (μmol/L)           | 7000.0   | 0.0—55.0        |
| ALT (U/L)                       | 17       | 10—42          | β-Hydroxybuterate (μmol/L)      | 19020.0  | 0.0—85.0        |
| LDH (U/L)                       | 376      | 124—222        |                                 |          |                 |
| ALP (U/L)                       | 367      | 106—322        | Blood Gas Analysis              |          |                 |
| γ-GTP (U/L)                     | 33       | 13—64          | pH                              | 7.058    | 7.360—7.460     |
| BUN (mg/dL)                     | 43       | 8—20           | PCO2 (mmHg)                     | 18.2     | 34.0—46.0       |
| Creatinine (mg/dL)              | 2.02     | 0.65—1.07      | PO2 (mmHg)                      | 144.0    | 80.0—90.0       |
| Cholinesterase (U/L)            | 525      | 240—486        | HCO3- (mEq/L)                   | 4.9      | 24.0—32.0       |
| Uric acid (mg/dL)               | 11.1     | 2.6—5.5        | BE (mEq/L)                      | -2.47    | -2.5—2.5        |
| Creatine Kinase (U/L)           | 212      | 41—153         | SO2 (%)                         | 98.7     | 95.0—98.0       |
| Amylase (U/L)                   | 1823     | 42—118         | Urinary test                     |          |                 |
| P-Amylase (U/L)                 | 47       | 19—53          | Urinary pH                       | 5.0      | 5.0—7.5         |
| CRP (mg/dL)                     | 2.18     | <0.14          | Urinary protein                  | -        | -               |
| Procalcitonin (ng/mL)           | 6.87     | 0.00—0.05      | Urinary sugar                    | 3+       | -               |
| Sodium (mmol/L)                 | 134      | 138—145        | Urinary ketone body              | 2+       | -               |
| Potassium (mmol/L)              | 4.5      | 3.6—4.8        | Urinary bilirubin                | -        | -               |
| Chloride (mmol/L)               | 86       | 101—108        | Urinary blood                    | -        | -               |
| IP (mg/dL)                      | 9.6      | 2.7—4.6        |                                 | -        | -               |
| Magnesium (mg/dL)               | 3.1      | 1.9—2.6        |                                 | -        | -               |

*AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *LDH* lactate dehydrogenase, *ALP* alkaline phosphatase, *γ-GTP* γ-glutamyltranspeptidase, *BUN* blood urea nitrogen, *P-Amylase* Pancreatic-Amylase, *CRP* C-reactive protein, *IP* Inorganic Phosphorus, *LDL* Low-density lipoprotein, *HDL* High-density lipoprotein, *BE* Base Excess

**Discussion**

DKA is the most serious acute metabolic complication of DM, sometimes leading to life-threatening situations. At 62-years-of-age, our patient was implanted with a cardiac pacemaker for the treatment of sick sinus syndrome. At the time of admission with partial consciousness followed by a sudden drop in blood pressure, we diagnosed and treated the
Fig. 1 Clinical time course and biological monitor readings in the subject during DKA therapy period. To maintain serum potassium levels, 0.9% NaCl together with drip infusion and continuous insulin infusion were administered. Blood pressure suddenly and markedly decreased. Heart rate was 50 beats/min without fluctuation (②). To maintain blood pressure, the pacemaker was configured to 80 beats/min (③). The pacemaker was configured to 40 beats/min to confirm a spontaneous heartbeat (④). About 24 hours after a marked decrease of blood pressure, a spontaneous heartbeat was transiently observed by biological monitor (⑤). And about hours later, a spontaneous heartbeat was steadily observed (⑥).
patient for DKA-induced near-sinus arrest. We considered that the inserted cardiac pacemaker maintained a regular pulsation. In addition, the patient had no abnormalities such as ischemic heart disease, pulmonary thromboembolism and aortic dissection. This case report indicates that clinicians should know the possibility of DKA-induced critical conditions.

Under DKA conditions, sick sinus syndrome is aggravated by electrolyte abnormalities such as elevation of serum potassium. After intravenous insulin infusion to treat DKA, potassium replacement is required to prevent insulin therapy-induced hypokalemia. Therefore, both hyperkalemia and hypokalemia are closely involved in the development of arrhythmia and asystole under acidosis with DKA [2, 3]. It is also possible that hypophosphatemia is involved in the deterioration of sick sinus syndrome. Our patient fell into hypovolemic shock in association with DKA and sinus arrest, and after the treatment and recovery from DKA, hypovolemic shock did not recur. Although electrolyte imbalance in serum is not necessarily observed, intracellular electrolyte imbalance could be involved in the process. Therefore, it is likely that the intracellular electrolyte imbalance and metabolic acidosis led to the electrocardiogram abnormality which finally caused the reduction in heart rate and profound hypotension in this subject.

Moreover, if a patient with a pacemaker was complicated with hyperkalemia, hyperkalemia can cause loss of capture by a cardiac rhythm device without DKA [4]. Our patient’s initial potassium level was 4.4 mEq/L under sick sinus syndrome with an inserted cardiac pacemaker, although failure to capture is usually seen when potassium level reaches around 7 mEq/L. The American Diabetes Association Statements show that it is appropriate to start 20–30 mEq potassium in each liter of intravenous fluid in order to keep serum potassium between 4–5 mEq/L when starting potassium level is 3.3–5.2 mEq/L [1]. In emergency room, her potassium level was 4.6 mmol/L, and we started 0.9% NaCl and transferred her to a high care unit. About 2 hours later her potassium level was 3.9 mmol/L, and we started infusion of potassium with 20 mEq potassium (potassium L-asparta or potassium chloride). We assume that intracellular electrolyte imbalance was, at least in part, associated with sinus arrest in this subject. On the other hand, since it is known that dexmedetomidine causes atioventricular block and sinus arrest, it is possible that dexmedetomidine led to deterioration of heart function [5].

Taken together, it is likely that DKA was closely associated with sick sinus syndrome and that the intracellular electrolyte imbalance and metabolic acidosis led to the electrocardiogram abnormality which finally caused the reduction in heart rate and profound hypotension in this subject. We should bear in mind the possibility that DKA by electrolyte imbalance causes deterioration of sick sinus syndrome leading to prolonged sinus arrest.

Acknowledgements We thank Dr. Askew David (University of Occupational and Environmental Health, Japan) for English Language editing and review.

Author contribution TA researched data and wrote the manuscript. KT and RS researched data and contributed to the discussion. SK and HK reviewed the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standard All procedures followed were in accordance with the ethical standards of the responsible national committee on human experimentation and with the Declaration of Helsinki 1975, as revised in 2008.

Human and animal rights All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1964.

Informed consent Informed consent was obtained from the patient for being included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kitabchi AE, Umpierrez GE, Miles JM et al (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32:1335–43
2. Weiss JN, Qu Z, Shivkumar K (2017) Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 10(3):e004667
3. Abdulaziz S, Dabbagh O, Al Daker MO et al (2012) Hypokalemia and refractory asystole complicating diabetic ketoacidosis, lessons for prevention. BMJ Case Rep 2012:bcr-2012-007312
4. Barold SS, Herweg B (2014) The effect of hyperkalaemia on cardiac rhythm devices. Europace 16:467–76
5. Takata Kotaro, Adachi Yushi U, Suzuki Katsumi et al (2014) Dexmedetomidine-induced atrioventricular block followed by cardiac arrest during atrial pacing: a case report and review of the literature. J Anesth 28:116–120

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.